Tufts Clinical and Translational Science Institute (N3C Supplement)
Tufts Clinical and Translational Science Institute (N3C Supplement)
批准号:
10172199
负责人:
Harry P. Selker
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2023-04-30
关键词:
AwardCOVID-19CaringCenter for Translational Science ActivitiesClinical DataClinical ResearchClinical SciencesCollaborationsCommunitiesDataDevelopmentDiagnosticDiseaseEmergency SituationEnsureEnvironmentFundingGoalsHealthHealth Care ResearchHealth PolicyInformaticsInstitutesKnowledgeMachine LearningMissionOutcomePatientsPharmaceutical PreparationsPlayProviderPublic HealthResearchResearch PersonnelResource SharingResourcesRiskRoleScienceSecureSpeedStandardizationStructureSystemTimeTranslational ResearchTranslationsTreatment EfficacyUnited States National Institutes of HealthUpdateVaccinesanalytical toolbasebench to bedsidecare deliveryclinical data warehouseclinical decision supportclinical practicecohortcollaborative approachconvictcoronavirus diseasedata integrationdata sharingdata warehouseeffective therapyhealth managementimprovedinformatics toolinnovationinsightinteroperabilitymeetingsnext generationnovel strategiespandemic diseaseprogramsrepositoryresponsesocial determinantssupport toolstool
中文摘要
项目摘要
塔夫茨临床和转化科学研究所(Tufts CTSI)基于以下信念:
整个临床和转化研究(CTR)的真实参与是
这对实现生物医学科学满足公众需求的承诺至关重要。这
不仅包括从工作台到床边的平移(T1平移),而且至关重要的是,
具有健康影响,转化为有效的临床实践(T2),护理提供和公众
健康(T3)和健康政策(T4)。所有这些方面的进展越来越依赖于
有效利用来自多个领域的科学数据。
COVID-19全球紧急情况既是一个紧迫的挑战,也是一个机遇,
NIH强调的重要数据共享目标的进展。作为回应,NCATS和
转化科学奖中心(CTSA)中心,几个HHS机构和其他
合作组织致力于开发下一代临床知识库,
与COVID-19相关的数据,国家COVID队列协作(N3 C),作为一种手段,
加速全球对该疾病的研究并帮助诊断技术的发展,
治疗剂和有效的疫苗。N3 C计划的目标是提高效率,
临床数据分析的可访问性与以下主要信息学目标一致:
塔夫茨CTSI,这是为了减少障碍,整合医疗保健和研究,
提供创新的系统、数据存储库和分析工具,
通过互操作性、标准化和资源共享实现交流和协作。在-
根据共同的目标,在本补编中,我们寻求为N3 C倡议做出贡献,
数据提供商和思想合作伙伴通过以下具体目标:(1)继续发挥
为N3 C的分析平台提供工具和资源的重要角色;以及(2)确保Tufts
CTSI的信息学计划有足够的工作人员和技术资源,继续提供
COVID特定患者数据从我们的中心到N3 C存储库。
英文摘要
PROJECT SUMMARY
Tufts Clinical and Translational Science Institute (Tufts CTSI) is based on the conviction that
authentic involvement of the entire spectrum of clinical and translational research (CTR) is
critical to fulfilling the promise of biomedical science for meeting the public's needs. This
includes not only from translation from bench to bedside (T1 translation), but also, crucially for
having health impact, translation into effective clinical practice (T2), care delivery and public
health (T3), and health policy (T4). Advances on all of these fronts is increasingly dependent on
making effective use of scientific data from multiple domains.
The COVID-19 global emergency presents both an immediate challenge and an opportunity to
progress on important data sharing aims emphasized by NIH. In response, NCATS and the
Centers for Translational Science Award (CTSA) hubs, several HHS agencies, and other
partnering organizations have committed to developing a next-generation repository for clinical
data related to COVID-19, the National COVID Cohort Collaborative (N3C), as a means of
accelerating global research into the disease and aiding the development of diagnostics,
therapeutics, and effective vaccines. The N3C initiative's goal of improving the efficiency and
accessibility of analyses with clinical data is consistent with the primary informatics objectives of
Tufts CTSI, which am to reduce barriers to the integration of healthcare and research by
providing innovative systems, data repositories, and analytical tools, and by enabling greater
exchange and collaboration through interoperability, standardization, and resource sharing. In-
line with shared objectives, in this supplement we seek to contribute to the N3C initiative as a
data provider and thought partner through the following specific aims: (1) continue to play an
important role providing tools and resources for N3C's analytics platform; and (2) ensure Tufts
CTSI's Informatics Program has sufficient staff and technical resources to continue to provide
COVID-specific patient data from our hub to the N3C repository.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)
-
批准号:10844980
-
项目类别:
-
资助金额:$97.51万
-
财政年份:2023
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Science Institute
-
批准号:10622002
-
项目类别:
-
资助金额:$1139.42万
-
财政年份:2023
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Science Institute
-
批准号:9816143
-
项目类别:
-
资助金额:$13.45万
-
财政年份:2018
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Science Institute
-
批准号:10159334
-
项目类别:
-
资助金额:$943.36万
-
财政年份:2018
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Science Institute
-
批准号:10412102
-
项目类别:
-
资助金额:$966.99万
-
财政年份:2018
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Science Institute (Pilot Supplement)
-
批准号:10260036
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2018
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8743320
-
项目类别:
-
资助金额:$42.47万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:9278321
-
项目类别:
-
资助金额:$447.83万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8720923
-
项目类别:
-
资助金额:$247.28万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8720917
-
项目类别:
-
资助金额:$41.85万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:9064892
-
项目类别:
-
资助金额:$594.81万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8720912
-
项目类别:
-
资助金额:$26.56万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8916328
-
项目类别:
-
资助金额:$8.94万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8865730
-
项目类别:
-
资助金额:$43.01万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8743321
-
项目类别:
-
资助金额:$53.12万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:9120456
-
项目类别:
-
资助金额:$60.03万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:9287937
-
项目类别:
-
资助金额:$38.46万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8897473
-
项目类别:
-
资助金额:$35.43万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:9140205
-
项目类别:
-
资助金额:$121.73万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
Tufts Clinical and Translational Research Institute
-
批准号:8865732
-
项目类别:
-
资助金额:$446.22万
-
财政年份:2013
-
负责人:Harry P. Selker
-
依托单位:
国内基金
海外基金
登录
查看更多内容
CEACAM5调控Galectin-9介导的CD4+T细胞极化在COVID-19肠屏障损伤的作用机制研究
-
批准号:82370569
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:李啸峰
-
依托单位:
COVID-19疫情对我国儿童生长发育影响的异质性研究
-
批准号:42371429
-
项目类别:面上项目
-
资助金额:52.00万元
-
批准年份:2023
-
负责人:张知新
-
依托单位:
传染病模型的稳态切换过程研究及其在治疗COVID-19中的应用
-
批准号:LQ23A010016
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:罗敏
-
依托单位:
“湿漫膜原”视角下研究加味达原饮重塑COVID-19“免疫炎症稳态”的分子机制:TLR4介导IRF3/NF-κB通路串扰
-
批准号:82374291
-
项目类别:面上项目
-
资助金额:48万元
-
批准年份:2023
-
负责人:张传涛
-
依托单位:
COVID-19中线粒体囊泡抑制CD8+T细胞记忆分化的机制研究
-
批准号:82300018
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:利时雨
-
依托单位:
COVID-19疫情爆发后武汉地区儿童副流感病毒3型的流行趋势和进化规律研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:
-
依托单位:
基于 GDF15-IL6 信号轴探究扶正解毒方逆转血管内皮衰老治疗COVID-19的作用与机制
-
批准号:82374392
-
项目类别:面上项目
-
资助金额:48万元
-
批准年份:2023
-
负责人:张忠德
-
依托单位:
COVID-19疫苗同源、异源加强剂次细胞免疫与体液免疫效应的前瞻性队列研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:蔡琳
-
依托单位:
多维不平稳和长记忆性的复杂整值时间序列的建模及其在Covid-19研究中的应用
-
批准号:12301358
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:许晓菲
-
依托单位:
基于人源细胞3D培养和精密肺切片技术探讨慢阻肺患者COVID-19易感机制研究
-
批准号:LY23H190003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:钱国清
-
依托单位: